Skip to main content
. 2021 Mar 13;25(8):2430–2440. doi: 10.1007/s10461-021-03205-z

Table 4.

Acceptability of the dapivirine vaginal ring at PUEV, based on all months of use, by country

Malawi South Africa Uganda Zimbabwe Total
N (%) N (%) N (%) N (%) N (%)
Total 259 (100) 1136 (100) 238 (100) 637 (100) 2270 (100)
PUEV study month—mean, median (IQR) 14.4, 13 (11–16) 20.3, 24 (13–27) 21.9, 22 (19–27) 18.9, 19 (13–24) 19.4, 20 (13–27)
Use attributes
 Problematic change to vaginal environmenta 19 (7) 125 (11) 19 (8) 24 (4) 187 (8)
  Vagina wetter 13 (5) 109 (10) 13 (5) 20 (3) 155 (7)
  Vagina drier 6 (2) 16 (1) 6 (3) 4 (1) 32 (1)
 Mind wearing the ring during mensesa 90 (35) 93 (8) 183 (77) 6 (1) 372 (16)
  Did not have menses during the study 24 (9) 147 (13) 20 (8) 26 (4) 217 (10)
Effects on sex
 Mind wearing the ring during sexa 90 (35) 109 (10) 203 (85) 2 (< 1) 404 (18)
  Did not have sex during the study 4 (2) 13 (1) 0 (0) 1 (< 1) 18 (1)
 Ring's effect on sexual pleasurea,b
  Increases sexual pleasure 152 (59) 358 (32) 85 (36) 283 (44) 878 (39)
  Decreases sexual pleasure 4 (2) 44 (4) 10 (4) 3 (1) 61 (3)
  No change to sexual pleasure 99 (38) 719 (63) 143 (60) 350 (55) 1311 (58)
Partner’s attitude
 Ring was acceptable to partnera
  Yes 231 (89) 794 (70) 101 (42) 484 (76) 1610 (71)
  No 15 (6) 142 (13) 59 (25) 34 (5) 250 (11)
  Don’t know 13 (5) 199 (18) 78 (33) 119 (19) 409 (18)
 Partner ever asked you to stop wearing the ringa 20 (8) 158 (14) 27 (11) 34 (5) 239 (11)
Overall acceptability, future likelihood of ring usea,c
 Very likely 149 (58) 673 (59) 185 (78) 496 (78) 1503 (66)
 Likely 82 (32) 398 (35) 49 (21) 140 (22) 669 (30)
 Unlikely 16 (6) 28 (3) 2 (1) 1 (0) 47 (2)
 Very unlikely 12 (5) 36 (3) 2 (1) 0 (0) 50 (2)

PUEV product use end visit, IQR interquartile range

aSignificantly different by country, p < 0.001

bMissing response: Malawi (N = 4), South Africa (N = 15), Zimbabwe (N = 1)

cMissing response: South Africa (N = 1)